увеальная меланома1.Бровкина А.Ф., Вальский В.В., Гусев Г.А. и др. Офтальмоонкология. Руководство для врачей. Под ред. А.Ф.Бровкиной. М.: Медицина, 2002.2.Гришина Е.Е., Федотова О.Ф., Житенев В.П. Анализ офтальмоонкологоческой патологии у взрослого населения Москвы по данным МОКБ. Сб. научн. трудов "Опухоли и опухолеподобные заболевания органа зрения". М., 1998; 28–313.Singh A.D., Shields C.L., Shields J.A. Prognostic factors in uveal melanoma. Melanoma Res 2001; 11: 255–63.4.Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No.26. Arch Ophthalmol 2005; 123: 1639–43.5.Diener-West M, Reynolds M.S., Agugliaro J.D. et al. Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report No.23. J Clin Oncol 2004; 22 (12): 2438–44.6.Albert D.M., Niffennegger A.S., Willson J.K.V. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36: 429–38.7.Leyvraz S, Spataro V, Bauer J et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Clin Oncol 1997; 15: 2589–95.8.Зиангирова Г.Г., Лихванцева В.Г. Опухоли сосудистого тракта глаза. М.: Последнее слово, 2003.9.Pe’er J, Amer R, Kaiserman I. The value of screening tests for metastatic uveal melanoma. Final programme and abstract book 2001; 144.10.Gombos D.S., Van Quill K.R., Uusitalo M, O'Brien J.M. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology 2004;111 (12): 2254–8.11.Robinson P.J. Imaging liver metastases: current limitations and future prospects. Br J Radiol 73 (867): 234–41.12.Eskelin S, Pyrhonen S, Summanen P et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999; 85: 1151–9.13.Bedikian A.Y., Legha S.S., Mavligit G et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76 (9): 1665–70.14.Gore R.M., Levine M.S., Laufer I. Textbook of gastrointestinal radiology. Philadelphia, PA: WB Saunders 1994; 1935.15.Grainger R.G., Allison D.J. Diagnostic radiology: a textbook of medical imaging. New York: Churchill Livingstone, 1998; 1169.16.Sillaire-Houtmann I, Bonafous J, Veyre A et al. Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. Fr Ophtalmol 2004; 27 (1): 34–9.17.Lindholm P, Minn H, Leskinen-Kallio S et al. Influence of the blood glucose concentration on FDG uptake in cancer a PET study. Nucl Med 1993; 34: 1–6.18.Francken A.B., Fulham M.J., Millward M.J., Thompson J.F. Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Surg Oncol 2006; 32 (7): 780–4.19.Schoder H, Larson S.M., Yeung H.W.D. PET/computed tomography in oncology integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. Nucl Med 2004; 45: 72S–81.20.Cohade C, Osman M, Leal J, Wahl R. Direct comparison of 18 F-FDG PET and PET/CT in patients with colorectal carcinoma./Nucl Med 2003; 44: 1797–803.21.Eskelin S, Pyrhönen S, Summanen P, Prause J.U., Kivelä T. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999; 85 (5): 1151–9.22.Eskelin S, Kivelä T. Imaging to Detect Metastases From Malignant Uveal Melanoma. Arch Ophthalmol 2002; 120: 676.23.Missotten G.S., Korse C.M., van Dehn C et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 2007; 28 (2): 63–9.24.Felberg N.T., Shields J.A., Maguire J et al. Gamma - glutamyl transpeptidase in the prognosis of patients with uveal malignant melanoma. Am J Ophthalmol 1983; 95 (4): 467–73.25.Kaiserman I, Amer R. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 2004; 137 (2): 236–43.26.Callejo S.A., Marshall J.C., Cools-Lartigue J et al. Macrophage - derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro. Melanoma Res 2004; 14 (2): 91–5.27.Reiniger I.W., Schaller U.C., Haritoglou C et al. Melanoma inhibitory activity (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005; 243 (11): 1161–6.28.Schaller U.C., Mueller A.J., Bosserhoff A.K. et al. Melanoma inhibitory activity (MIA). Evaluation of a new tumor - associated antigen as a serum marker for uveal melanomas. Ophthalmologe 2000; 97 (6): 429–32.29.Schaller U.C., Bosserhoff A.K., Neubauer A.S. et al. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res 2002;(6): 593–9.30.Loppin M, Quillien V, Adamski H et al. Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma. Ann Dermatol Venereol 2007; 134 (6–7): 535–40.31.Djukanovic D, Hofmann U, Sucker A et al. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000;20 (3B): 2203–7.32.Kadkol S.S., Lin A.Y., Barak V et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 2006;47 (3): 802–6.33.Reiniger I.W., Wolf A, Welge-Lüssen U et al. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 2007; 143 (4): 705–7.34.Barak V, Frenkel S, Kalickman I et al. Serum markers to detect metastatic uveal melanoma. Anticancer Res 2007; 27 (4A): 1897–900.35.Лихванцева В.Г., Слепова О.С., Бpовкина А.Ф. Интеpфеpоновый статус пpи увеальной меланоме. Вестн. офтальмол. 1999; 115 (6): 35–7.36.Лихванцева В.Г., Бровкина А.Ф., Слепова О.С. Способ прогнозирования клинического течения увеальной меланомы. Патент Российской Федерации на изобретение RU 2149404 C1, 7 G01N33/53. 05.20.2000. Регистрационный номер заявки: 99106475/14.37.Гольдман Э.М., Гутенко А.И. Значение лабораторных исследований в прогнозе злокачественной увеальной меланомы. Актуальные вопросы биохимии человека и животных. Сб. статей Казахстанского отделения Всесоюзного биохимического общества, Алма-Ата, 1990; 21–2.38.Андреева Л.Д., Лихванцева В.Г. Иммуногистохимический анализ апоптоза, интерлейкина-2 и ядерного антигена пролиферации при увеальной меланоме. Опухоли и опухолеподобные заболевания органа зрения. Cб. научных трудов. М., 1998; 10–2.39.Ren D.H., Mayhew E, Hay C et al. Uveal melanoma expression of tumor necrosis factor - related apoptosis - inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. Invest Ophthalmol Vis Sci 2004;(4): 1162–8.40.Слепова О.С. и др. Фактор некроза опухоли - альфа при увеальной меланоме. Офтальмологич. журн. 1998; 5: 357–60.41.Бровкина А.Ф., Вальский В.В., Зарубей Г.Д. Метастатическое поражение печени у больных с увеальной меланомой. Вестн. офтальмол., 1998;114 (1): 21–3.42.Callejo S.A., Antecka E, Blanco P.L. et al. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007; 21 (6): 752–9.43.Schuster R, Bechrakis N.E., Stroux A et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 2007; 13 (4): 1171–8.44.Keilholz U, Goldin-Lang P, Bechrakis N.E. et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real - time reverse transcriptase - polymerase chain reaction. Clin Cancer Res 2004; 10 (5): 1605–12.45.Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-Infiltrating Macrophages (CD68+ Cells) and Prognosis in Malignant Uveal Melanoma. Invest Ophthalmol Vis Sci 2001; 42: 1414–21.46.Niederkorn J.Y., Wang S. Immunology of intraocular tumors. Ocul Immunol Inflamm 2005; 13 (1): 105–10.47.Верещагина М.В., Лихванцева В.Г., Анурова О.А. Клинические и иммуногистохимические параллели в диагностике опухолей сосудистого тракта глаза и в прогнозировании неопластического процесса. Автореф. дис.. канд. мед. наук. М., 2006.48.Toivonen P, M?kitie T, Kujala E, Kivelä T. Microcirculation and Tumor- Infiltrating Macrophages in Choroidal and Ciliary Body Melanoma and Corresponding Metastases. Invest Ophthalmol Vis Sci 2004; 45: 1–6.49.Folberg R, Chen X, Boldt H.C. et al. Microcirculation patterns other than loops and networks in choroidal and ciliary body melanomas. Ophthalmology 2001; 108 (5): 996–1001.50.Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. Natl Cancer Inst 1999; 91 (4): 359–67.51.Астахова С.Е., Лихванцева В.Г., Ухов Ю.И. и др. Маркеры ангиогенеза в прогнозе увеальной меланомы. Мед. иммунол. 2003; 5 (3–4): 346.52.Scholes A.G., Damato B.E., Nunn J et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44 (3): 1008–11.53.Gambrelle J, Labialle S, Dayan G et al. Toward monosomy 3 as the main prognosis factor of uveal melanoma: current cytogenetic data. Fr Ophtalmol 2004; 27: 1061–7.54.Desjardins L, Levy-Gabriel C, Lumbroso-Lerouic L et al. Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. Fr Ophtalmol 2006; 29 (7): 741–9.55.Nareyeck G, Zeschnigk M, Prescher G et al. Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3. Exp Eye Res 2006; 83 (4): 858–64.56.Tschentscher F, Hüsing J, Hölter T et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy represent two distinct entities. Cancer Res 2003; 63 (10): 2578–84.57.Maat W, Jordanova E.S., van Zelderen-Bhola S.L. et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine - needle aspiration biopsies. Arch Pathol Lab 2007;(1): 91–6.58.Maat W, Long V.L., Jordanova E.S. et al. Monosomy of Chromosome 3 and an Inflammatory Phenotype Occur Together in Uveal Melanoma. Invest Ophthalmol Vis Sci 2008; 49: 505–10.59.Onken M.D., Worley L.A., Person E et al. Loss of heterozygosity of chromosome detected with single nucleotide polymorphisms is superior to monosomy for predicting metastasis in uveal melanoma. Clin Cancer Res 2007;(10): 2923–7.60.Häusler T, Stang A, Anastassiou G et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 2005; 116 (6): 909–13.61.Meir T, Zeschnigk M, Masshöfer L et al. The spatial distribution of monosomy and network vasculogenic mimicry patterns in uveal melanoma. Invest Ophthalmol Vis Sci 2007; 48 (5): 1918–22.62.Worley L.A., Onken M.D., Person E et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 2007; 13 (5): 466–71.63.Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205–9.64.Tschentscher F, Husing J, Holter T et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy represent two distinct entities. Cancer Res 2003; 63: 2578–84.65.Вит В.В., Величко Л.Н., Драгомирецкая Е.И. Возможность прогнозирования клеточного типа увеальных меланом без использования инвазивных методов диагностики. Онкология. 2002; 4 (4): 259–62.66.Midena E, Bonaldi L, Parrozzani R et al. Loss ofIn vivo detection of monosomy in eyes with medium - sized uveal melanoma using transscleral fine needle aspiration biopsy. Eur J Ophthalmol 2006; 16 (3): 422–2.